详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

NGS Sequencing Based Liquid / Tissue Biopsy Identified Coexistence of HER2 Amplification and Mutation in Advanced NSCLC Patients

文献详情

资源类型：

作者：

机构： [1]Geneplus Beijing, Beijing, Peoples R China; [2]Beijing Canc Hosp, Beijing, Peoples R China; [3]Fujian Prov Canc Hosp, Fuzhou, Fujian, Peoples R China; [4]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Hubei, Peoples R China; [5]Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [6]Chinese Acad Med Sci, Canc Inst & Hosp, Beijing, Peoples R China; [7]Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China; [8]Shanghai Chest Hosp, Shanghai, Peoples R China; [9]Air Force Gen Hosp, Beijing, Peoples R China; [10]Fujian Canc Hosp, Fuzhou, Fujian, Peoples R China; [11]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China; [12]Zhejiang Canc Inst, Hangzhou, Zhejiang, Peoples R China; [13]Zhejiang Rongjun Hosp, Jiaxing, Peoples R China

出处：

DOI：

ISSN：

关键词： next generation sequencing (NGS) ctDNA HER2 amplification and mutation

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

第一作者：

第一作者机构： [1]Geneplus Beijing, Beijing, Peoples R China;

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Detection of ERBB2 (HER2) amplification by next-generation sequencing (NGS) in patients (pts) with gastrointestinal (GI) cancer [2]Profile of Next-Generation Sequencing (NGS) on MET exon 14 Skipping Mutation and MET Amplification in Lung Cancer: A Calibration Project in China [3]Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients [4]MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. [5]ctDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) [6]Perioperative ctDNA-Based MRD Detection in NSCLC-Response [7]Perioperative ctDNA-Based MRD Detection in NSCLC-Response [8]Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405) [9]基于ctDNA进行肺癌患者术后监测 [10]Ultrasensitive tumour-agnostic non-invasive detection of colorectal cancer recurrence using ctDNA methylation